Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 593-615

  Gomaraschi, Monica ^a   Adorni, Maria Pia ^b   Banach, Maciej ^c   Bernini, Franco ^b   Franceschini, Guido ^a   Calabresi, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cell cholesterol efflux; Endothelial cells; Fibrates; HDL; HDL subclasses; Niacin; Statins

Indexed keywords

APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HEME OXYGENASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROSTACYCLIN; ROSUVASTATIN; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENZYME INHIBITION; FATTY ACID OXIDATION; GASTROINTESTINAL DISEASE; HOMEOSTASIS; HOT FLUSH; HUMAN; HYDROLYSIS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID PEROXIDATION; LIVER DYSFUNCTION; OXIDATIVE STRESS; PARTICLE SIZE; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; HYPERLIPIDEMIAS; METABOLISM; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; ENDOTHELIAL CELLS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84919608591     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_19     Document Type: Conference Paper

References (137)

1. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH (2007) The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 48:2453–2462
2. Alaupovic P, Hodis HN, Knight Gibson C, Mack WJ, LaBree L, Cashin Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH (1994) Effects of lovastatin on ApoA- and ApoB-containing lipoproteins families in a subpopulation of patients participating in the monitored atherosclerosis regression study (MARS). Arterioscler Thromb 14:1906–1913
3. Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J (2008) Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol 102:1341–1347
4. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C (2012) Statins as antiinflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18:1519–1530
5. Arii K, Suehiro T, Ota K, Ikeda Y, Kumon Y, Osaki F, Inoue M, Inada S, Ogami N, Takata H, Hashimoto K, Terada Y (2009) Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 202:439–445
6. Asztalos BF, Schaefer EJ (2003) High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91:12E–17E
7. Asztalos BF, Horvath K, McNamara J, Roheim P, Rubinstein J, Schaefer E (2002a) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164:361–369
8. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ (2002b) Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43:1701–1707
9. Asztalos BF, Le MF, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ (2007) Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 99:681–685
10. Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ (2008) Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the veterans affairs high-density lipoprotein intervention trial. Metabolism 57:77–83
11. Avogaro A, Miola M, Favaro A, Gottardo L, Pacini G, Manzato E, Zambon S, Sacerdoti D, de Kreutzenberg S, Piliego T, Tiengo A, Del Prato S (2001) Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest 31:603–609
12. Bard JM, Luc G, Douste-Blazy P, Drouin P, Ziegler O, Jacotot B, Dachet C, de Gennes JL, Fruchart JC (1989) Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia. Eur J Clin Pharmacol 37:545–550
13. Barter PJ, Baker PW, Rye KA (2002) Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 13:285–288
14. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122
15. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 51:1546–1553
16. Benjo AM, Maranhao RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, Brandizzi LI, da Luz PL (2006) Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 187:116–122
17. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244–251
18. Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, Jukema JW (2007) Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 23:2235–2240
19. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45:185–197
20. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267
21. Bodor ET, Offermanns S (2008) Nicotinic acid: an old drug with a promising future. Br J Pharmacol 153(Suppl 1):S68–S75
22. Bregar U, Jug B, Keber I, Cevc M, Sebestjen M (2013) Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessel 29 (3):313–319
23. Broncel M, Cieslak D, Koter-Michalak M, Duchnowicz P, Mackiewicz K, Chojnowska-Jezierska J (2006) The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia. Pol Merkur Lekarski 20:547–550
24. Calabresi L, Franceschini G, Sirtori CR, de Palma A, Saresella M, Ferrante P, Taramelli D (1997) Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 238:61–65
25. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G (2002) Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22:656–661
26. Calabresi L, Gomaraschi M, Franceschini G (2003) Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23:1724–1731
27. Calabresi L, Gomaraschi M, Franceschini G (2010) High-density lipoprotein quantity or quality for cardiovascular prevention? Curr Pharm Des 16:1494–1503
28. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald WT (1986) Fifteen year mortality in coronary drug project patients: longterm benefit with niacin. J Am Coll Cardiol 8:1245–1255
29. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15:1987–1994
30. Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113:2548–2555
31. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 29:870–876
32. De Lalla OF, Gofman JW (1954) Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal 1:459–478
33. De Vries R, Kerstens MN, Sluiter WJ, Groen AK, Van TA, Dullaart RP (2005) Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 48:1105–1113
34. Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285–1295
35. Dullaart RP, De VR, Voorbij HA, Sluiter WJ, Van TA (2009) Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur J Clin Invest 39:200–203
36. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A (2000) Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101:1773–1779
37. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48:11067–11074
38. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP (2008) Multiple actions of highdensity lipoprotein. Curr Opin Cardiol 23:370–378
39. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR (1989) Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med 114:250–259
40. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR (2007) Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195:385–391
41. Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R (2013) Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol 7:414–422
42. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M (2002) Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164:179–185
43. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML (2009) Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202:68–75
44. Ghani RA, Bin YI, Wahab NA, Zainudin S, Mustafa N, Sukor N, Wan Mohamud WN, Kadir KA, Kamaruddin NA (2013) The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. J Clin Lipidol 7:446–453
45. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574
46. Gomaraschi M, Basilico N, Sisto F, Taramelli D, Eligini S, Colli S, Sirtori CR, Franceschini G, Calabresi L (2005) High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 1736:136–143
47. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ (2000) Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189–197
48. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ (2002) Dosedependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163:287–296
49. Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ (2003) Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 88:3738–3746
50. Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovicky R, Cohen R, Hayek T (2013) Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. Am J Med Sci 345:195–199
51. Harangi M, Seres I, Varga Z, Emri G, Szilvassy Z, Paragh G, Remenyik E (2004) Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 60:685–691
52. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnar M, Kassai A, Derdak Z, Illyes L, Paragh G (2009) Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 153:190–198
53. Hernandez M, Wright SD, Cai TQ (2007) Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 355:1075–1080
54. Higashi Y, Matsuoka H, Umei H, Sugano R, Fujii Y, Soga J, Kihara Y, Chayama K, Imaizumi T (2010) Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells. Am J Physiol Endocrinol Metab 298:E202–E209
55. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H (1995) Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 114:223–234
56. HPS2-THRIVE Collaborative Group (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34:1279–1291
57. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H (2007) Statins induce S1P(1) receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 150:470–479
58. Johansson J, Carlson LA (1990) The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects. Atherosclerosis 83:207–216
59. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152–160
60. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. Am J Cardiol 101:20B–26B
61. Kaplon RE, Gano LB, Seals DR (2014) Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J Appl Physiol (1985) 116:156–163
62. Kassai A, Illyes L, Mirdamadi HZ, Seres I, Kalmar T, Audikovszky M, Paragh G (2007) The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 40:1–5
63. Khera AV, Cuchel M, De LL-M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135
64. Khera AV, Patel PJ, Reilly MP, Rader DJ (2013) The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 62:1909–1910
65. Khoury N, Goldberg AC (2011) The use of fibric acid derivatives in cardiovascular prevention. Curr Treat Option Cardiovasc Med 13:335–342
66. Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, Kurose H, Murakami M, Okajima F (2008) Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol 181:7332–7340
67. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S (1998) Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47:1097–1104
68. Koh KK, Yeal AJ, Hwan HS, Kyu JD, Sik KH, Cheon LK, Kyun SE, Sakuma I (2004) Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174:379–383
69. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK (2005) Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45:1649–1653
70. Kontush A, Chapman MJ (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 21:312–318
71. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH (2002) A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:165–172
72. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH (2006) Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98:743–745
73. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJ (2008) Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoBcontaining lipoproteins. Arterioscler Thromb Vasc Biol 28:1672–1678
74. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP (2009) Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54:1787–1794
75. Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96:1221–1232
76. Liu Y, Wei J, Hu S, Hu L (2012) Beneficial effects of statins on endothelial progenitor cells. Am J Med Sci 344:220–226
77. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J (2001) Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial – FAT). Cardiovasc Res 52:290–298
78. Maranghi M, Hiukka A, Badeau R, Sundvall J, Jauhiainen M, Taskinen MR (2011) Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis 219:259–265
79. McGrath KC, Li XH, Puranik R, Liong EC, Tan JT, Dy VM, DiBartolo BA, Barter PJ, Rye KA, Heather AK (2009) Role of 3beta-hydroxysteroid-Delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 29:877–882
80. Miida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, Kashiwa T, Murakami T, Inano K, Okada M (2000) Bezafibrate increases Prebeta1-HDL at the expense of HDL(2b) in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 20:2428–2433
81. Mineo C, Shaul PW (2012) Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111:1079–1090
82. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G (2008) The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 66:366–374
83. Miyamoto-Sasaki M, Yasuda T, Monguchi T, Nakajima H, Mori K, Toh R, Ishida T, Hirata K (2013) Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb 20:708–716
84. Morgan JM, Capuzzi DM, Baksh RI, Intenzo C, Carey CM, Reese D, Walker K (2003) Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91:1432–1436
85. Morgan JM, De LL-M, Capuzzi DM (2007) Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. J Clin Lipidol 1:614–619
86. Muacevic-Katanec D, Bradamante V, Poljicanin T, Reiner Z, Babic Z, Simeon-Rudolf V, Katanec D (2007) Clinical study on the effect of simvastatin on paraoxonase activity. Arzneimittelforschung 57:647–653
87. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S (2009) Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 61:892–898
88. Nichols AV, Krauss RM, Musliner TA (1986) Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 128:417–431
89. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292–2300
90. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck LK, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113:569–581
91. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51:314–324
92. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 113:1556–1563
93. Paragh G, Seres I, Harangi M, Balogh Z, Illyes L, Boda J, Szilvassy Z, Kovacs P (2003) The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab 29:613–618
94. Patsch JR, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G (1984) Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest 74:2017–2023
95. Petoumenos V, Nickenig G, Werner N (2009) High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med 13:4623–4635
96. Philpott AC, Hubacek J, Sun YC, Hillard D, Anderson TJ (2013) Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis 226:453–458
97. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M (2008) Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196:122–128
98. Podrez EA (2010) Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol 37:719–725
99. Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO, Lerman A (2011) Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 18:704–716
100. Riwanto M, Landmesser U (2013) High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 54:3227–3243
101. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585–1591
102. Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR (2013) Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128:1256–1267
103. Rubic T, Trottmann M, Lorenz RL (2004) Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67:411–419
104. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162:2597–2604
105. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR (2007) The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 154:943–953
106. Sakai T, Kamanna VS, Kashyap ML (2001) Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 21:1783–1789
107. Sasaki J, Yamamoto K, Ageta M (2002) Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. Clin Ther 24:1614–1626
108. Schwartz GG, Olsson AG, Barter PJ (2013) Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med 368:869–870
109. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition on apolipoprotein A metabolism. J Clin Invest 63:858–867
110. Shuhei N, Soderlund S, Jauhiainen M, Taskinen MR (2010) Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis 9:104
111. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horvath T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, Von EA, Drexler H, Landmesser U (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extendedrelease niacin therapy. Circulation 121:110–122
112. Soudijn W, van Wijngaarden I, Ijzerman AP (2007) Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27:417–433
113. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM (1991) Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 266:11095–11103
114. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, Nestel P (2008) Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 197:732–739
115. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T (2007) Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 282:21090–21099
116. Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J (2007) Effects of reconstituted highdensity lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675–1682
117. The Bezafibrate Infarction Prevention (BIP) Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21–27
118. The FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861
119. Thoenes M, Oguchi A, Nagamia S, Vaccari CS, Hammoud R, Umpierrez GE, Khan BV (2007) The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 61:1942–1948
120. Tkac I, Molcanyiova A, Javorsky M, Kozarova M (2006) Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res 53:261–264
121. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20:2113–2119
122. Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP (2013a) Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 44(3):240–248
123. Triolo M, Kwakernaak AJ, Perton FG, De Vries R, Dallinga-Thie GM, Dullaart RP (2013b) Low normal thyroid function enhances plasma cholesteryl ester transfer in type 2 diabetes mellitus. Atherosclerosis 228:466–471
124. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD (2003) Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44:927–934
125. van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC (2007) Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 48:1763–1771
126. Vazzana N, Ganci A, Cefalu AB, Lattanzio S, Noto D, Santoro N, Saggini R, Puccetti L, Averna M, Davi G (2013) Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J Am Heart Assoc 2: e000063
127. Vega GL, Grundy SM (1994) Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 154:73–82
128. Wahlberg G, Walldius G, Olsson AG, Kirstein P (1990) Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med 228:151–157
129. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT (2003) Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170:315–323
130. Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, Walter U, Peetz D, Lackner K, Blankenberg S, Munzel T (2009) Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 204:216–221
131. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR (1999) High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 274:33143–33147
132. Yadav R, France M, Younis N, Hama S, Ammori BJ, Kwok S, Soran H (2012) Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother 13:1345–1362
133. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010) Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 17:436–451
134. Yesilbursa D, Serdar A, Saltan Y, Serdar Z, Heper Y, Guclu S, Cordan J (2005) The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol 62:526–530
135. Yetukuri L, Huopaniemi I, Koivuniemi A, Maranghi M, Hiukka A, Nygren H, Kaski S, Taskinen MR, Vattulainen I, Jauhiainen M, Oresic M (2011) High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS ONE 6:e23589
136. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW (2001) High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7:853–857
137. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR (2010) Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 30:1430–1438